scholarly journals Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

2012 ◽  
Vol 23 ◽  
pp. ixe21 ◽  
Author(s):  
A.T. Shaw ◽  
D.W. Kim ◽  
K. Nakagawa ◽  
T. Seto ◽  
L. Crinò ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Alk Positive ◽  
Docetaxel Chemotherapy

scholarly journals MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

2017 ◽  
Vol 12 (1) ◽  
pp. S378-S379 ◽  
Author(s):  
Young Kim ◽  
Toyoaki Hida ◽  
Hiroshi Nokihara ◽  
Masashi Kondo ◽  
Koichi Azuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Alk Positive
Sign in / Sign up

Export Citation Format

Share Document